Outcomes of Low-Grade Endometrial Stromal Sarcoma with Mario Leitao and Evan Smith

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Mario Leitao and Evan Smith to discuss outcomes of low-grade endometrial stromal sarcoma. Dr. Leitao is an attending surgeon and member at Memorial Sloan Kettering Cancer Center as well as a Professor at Weill Cornell Medical College. He serves as the fellowship director at MSKCC as well as the Director of the Minimally Invasive and Robotic Surgery Program. Dr. Smith is a gynecologic oncologist at Woman’s Hospital in Baton Rouge, Louisiana. He also serves as an Assistant Clinical Professor of Gynecologic Oncology with the LSU Health Obstetrics and Gynecology residency program in Baton Rouge. Highlights: -Lymphadenectomy is unnecessary in patients with low-grade endometrial stromal sarcoma (ESS) and clinically normal nodes. -Postoperative therapies do not improve progression-free survival (PFS) or overall survival in low-grade ESS that is completely resected. -FIGO stage is associated with PFS but not disease-specific survival.

-Next generation sequencing is standard for soft tissue sarcomas and should be offered to patients with low-grade ESS.